Future Market Insights delivers key insights on the global 3D printed medical devices market in a new publication titled “3D Printed Medical Devices Market: Global Industry Analysis and Opportunity Assessment, 2016 – 2026”. The global 3D printed medical devices market was estimated to be US$ 238 Mn in 2015 and it has a wide scope of growth in the forecast period. The global 3D printed medical devices market can be broadly classified into six segments depending on the technology namely – stereolithography (SLA), selective layer sintering (SLS), digital light processing (DLP), fused deposition modelling (FDM), polyjet / inkjet 3D printing, and electronic beam melting (EBM) – each with different applications that are specific to orthopaedic, dental, and internal and external prosthetics. The global 3D printed medical devices market is expected to reach US$ 279.6 Mn in 2016, witnessing a year-on-year growth of 17.5%.
Read Report Preview: https://www.futuremarketinsights.com/reports/3d-Printed-medical-devices-market
According to Future Market Insights analysts, factors such as a rising prevalence of disorders such as diabetes-related gangrene cases, peripheral vascular diseases, and osteoarthritis among elderly individuals are leading to the use of 3D printed medical devices. Some of the other factors are cases where dental implants and cranio-maxillofacial implants are required. These factors are collectively anticipated to fuel the revenue growth of the global 3D printed medical devices market over the forecast period. In addition, factors such as rising awareness regarding personal care, increasing prevalence of chronic diseases, increase in incidence of accidents, and increasing geriatric population are anticipated to enhance the growth of the global 3D printed medical devices market over the forecast period.
However, only a few selected materials such as resins, plastics and a few metals are used for 3D printing. Usage of other materials for 3D printing results in high operational costs and is time consuming. Also, size of the printer limits the size of the product and thus, it is a challenging job to produce parts of large industrial machines. Moreover, a key limiting factor in the adoption of 3D printing are technical barriers. These are complex equipment and so most of the 3D printing manufacturers are utilising open source technology. As adjusting equipment and printing parameters are time consuming processes, users lose interest in learning or knowing to operate such devices.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1501
By technology, the SLS technology segment accounted for a higher revenue share in the global 3D printed medical devices market in 2015 as compared to other product segments. The SLS technology segment is expected to reach a value of US$ 230.0 Mn by 2026, registering a CAGR of 15.3% over the forecast period. Though the value of the polyjet / inkjet 3D printed medical devices technology segment was lower as compared to the SLS technology segment in 2015, due to a growing demand and increasing applications, its value over the forecast period is expected to be the highest amongst the other categories in the technology segment.
By material, the plastics material segment accounted for a higher revenue share in the global 3D printed medical devices market as compared to others. The plastic material segment is expected to reach a value of US$ 984.7 Mn by 2026, registering a CAGR of 17.2% over the forecast period.
By application, the orthopaedic implants application segment accounted for a higher revenue share in the global 3D printed medical devices market as compared to other segments. The orthopaedic implants application segment is expected to reach a value of US$ 643.5 Mn by 2026, reflecting a CAGR of 19.9% over the forecast period.
Buy 3D Printed Medical Devices Market Research Report: https://www.futuremarketinsights.com/checkout/1501
By distribution channel, the hospitals end user segment accounts for higher demand for 3D printed medical devices as compared to other distribution channel segments such as ambulatory surgical centres and diagnostic centres, registering a CAGR of 18.7% over the forecast period.
Regional market projections
Sales of 3D printed medical devices are relatively healthy in the U.S. market in recent years, making North America the most lucrative market globally. The North America 3D printed medical devices market revenue was accounted to be US$ 105.0 Mn in 2015, with the U.S. accounting for a majority of revenue share. In addition to North America, 3D printed medical devices sales are expected to grow gradually in Western Europe, Eastern Europe, and APEJ. Revenues in Western Europe are expected to register a CAGR of 18.5%, whereas Eastern Europe is anticipated to register a CAGR of 15.6% over the forecast period.
Key players in the global 3D printed medical devices market include 3D Systems, Inc., Arcam AB, Stratasys Ltd., FabRx Ltd., EOS GmbH Electro Optical Systems, EnvisionTEC, Cyfuse Biomedical K.K., and Bio3D Technologies. Major market players are implementing different strategies and are launching new products in order to grow their market share.
The global respiratory devices market was valued at nearly US$ 13 billion in 2016. It is projected to grow at 9.2% CAGR during the period 2017-2027 to reach US$ 34.17 billion in revenues.
Demand for respiratory devices will continue to be driven by increasing ageing population and rising prevalence of COPD and obstructive sleep apnea. Increasing emphasis on healthcare spending in developing countries, especially in Asia Pacific and Latin America, will continue to positively influence the growth of the market.
Adoption of non-invasive techniques in pulse oximeters and advancement in full polysomnography testing are also favourably impacting the growth of the market.
Although Future Market Insights maintains a positive outlook on the global respiratory devices market, premium pricing, budgetary constraints, and increasing use of generic product types can impede the growth of the market.
View Report Preview: https://www.futuremarketinsights.com/reports/respiratory-devices-market
The key trends expected to influence the global respiratory devices market in the foreseeable future are,
Portable and wearable devices are steadily gaining popularity among patients owing to ease-of-use and flexibility in carrying the devices.
Growing demand for stationary oxygen concentrator with pulse flow technology and rechargeable batteries.
Increasing demand for respiratory devices in Asia Pacific on account of rising prevalence of chronic obstructive pulmonary diseases. Multinational companies are focusing on consolidating their position in developing countries to leverage upon the emerging opportunities.
Positive Airway Pressure Devices Account for the Highest Demand
According to Future Market Insights’ research, positive airway pressure devices currently account for the highest demand. This segment accounted for nearly 29% revenue share of the market in 2017; by 2027, this is projected to increase to 34.6%. In terms of revenues, positive airway pressure devices segment is projected to reach US$ 11.81 billion in revenues by 2027.
Other key product types by revenue are respiratory consumables (respiratory masks, nasal cannulas, tracheostomy tubes and oxygen tubes) and pulse oximeters.
Future Market Insights also offers market forecast and analysis on other key respiratory devices, including nebulisers, oxygen concentrators, polysomnography devices, mechanical ventilators, and spirometers.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-794
Hospitals Largest End-users
By end-user, the key segments include hospitals, ambulatory surgical centres, clinics, and long-term care centres. Currently, hospitals account for the highest demand for respiratory devices, followed by ambulatory surgical centres and long-term care centres. Demand for respiratory devices from hospitals was worth US$ 5.18 billion in 2016; by 2027, this is projected to grow at 9.8% CAGR to reach US$ 14.36 billion.
U.S. Continues to Account for Significant Percentage of Global Sales
The U.S. remains the largest market for respiratory devices globally. On the back of strong sales in the U.S., the North America respiratory devices market accounted for over 40% revenue share of the market in 2016. Future Market Insights projects North America to remain the largest market for respiratory devices during the period 2017-2027.
Western Europe and APEJ are the other leading markets for respiratory devices. These two markets collectively accounted for a revenue share of over 35% in 2016.
Future Market Insights, in its report, has also profiled the respiratory devices market in Latin America, Eastern Europe, Japan, and MEA.
In its report, companies profiled by Future Market Insights are Massimo Corporation, Teleflex Incorporated, Fisher & Paykel Healthcare Limited, ResMed Inc, Hamilton Medical AG, Medtronic PLC, Koninklijke Philips N.V., Smiths Medical, General Electric Healthcare Limited, Drägerwerk AG & Co. and KGaA, Inogen Inc.
A new report by Future Market Insights (FMI) anticipates the global soft tissue repair market to exhibit a steady 5.5% CAGR throughout the forecast period (2017-2022). The global market for soft tissue repair is expected to account for over US$ 15,000 Mn revenues by 2022-end.
Advancements in Products such as Bioabsorbable Soft Tissue Screws to Propel Growth of the Market
A number of technological advancements and innovations have been observed in orthopedic connective tissue repair procedures. Novel advances, for instance – the innovative surgical techniques, are being made in the procedures associated with anterior cruciate ligament (ACL) reconstruction, in a bid to make the process more effective. Global leaders, including Zimmer Biomet and NORAKER, have been developing new bioabsorbable soft tissue screws over the past few years. Leading market players have also been focusing on development of the mesh with biological products, which would act as a replacement for human allograft. An example of this is development of EZ Derm by MoInlycke Health Care, utilized as dressing for wounds using wires and pins independently, or together, with various other internal fixation devices. These devices are utilized for surgeries pertaining to hip replacement and spine.
View Report Preview: https://www.futuremarketinsights.com/reports/soft-tissue-repair-market
People across the globe are becoming aware of development, promotion, and commercialization of the advanced platelet-rich plasma devices, used for musculoskeletal disorders. In addition, there is a surge in awareness about skeletally immature patients to have a high risk of tear in the connective tissue and ligaments. These factors might positively impact global demand for soft tissue repair in the near future.
Sports-related Injuries- A Major Factor Driving the Market Growth
A major factor affecting demand for soft tissue repair is injuries related to sports. Athletes usually suffer from ACL tear during the game, or while performing other physical activities. Moreover, increasing aging population is also expected to play an imperative role in growth of the market. With aging, substantial changes are observed in skeletal and neuromuscular systems, which in turn leads towards ACL tear, weak ligaments and arthritis. Prevalence of obesity in geriatric population is directly increasing risk of degenerative bone diseases, such as osteoporosis and osteoarthritis. The aforementioned factors are further expected to increase demand for soft tissue repair procedures.
In contrast, high prices associated with soft tissue repair procedures, lack of awareness in population across underdeveloped and remote regions, and unfavorable reimbursement policies are factors which will impede demand for soft tissue repair procedures in the near future.
APEJ to Witness a Significant Expansion in the Market
The soft tissue repair market in Asia-Pacific excluding Japan (APEJ) is expected to witness a significant growth, with revenues poised to surpass US$ 3,000 Mn by 2022-end. Growth of the market in APEJ can be primarily attributed to increasing purchasing power of population, and rising prevalence of musculoskeletal disorders in countries such as India and China. In addition, North America is expected to remain the most attractive market for soft tissue repair, owing to the hike in healthcare expenditure in this region.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4931
Based on product, sales of laparoscopic instruments, and synthetic mesh are expected to collectively account for over one-third revenue share of the market during the forecast period. Sales of synthetic mesh and laparoscopic instruments will register similar CAGRs through 2022.
Orthopedic Application of Soft Tissue repair to Account for Largest Revenue Share
Orthopedic application of soft tissue repair are expected to account for the largest revenue share of the market during 2017 to 2022, followed by skin repair application. In addition, revenues from orthopedic and skin repair application of soft tissue repair are expected to collectively account for over US$ 7,000 Mn by 2022-end.
Accounting for around two-third revenue share of the market, hospitals are expected to remain the most lucrative end-users in the global market for soft tissue repair. Revenues from hospitals in the market are expected to reach approximately US$ 10,000 Mn by 2022-end.
Key players profiled by the FMI’s report, who are actively operating in the global soft tissue repair market, include Wright Medical Group N.V., Integra LifeScience Corporation, Medtronic Plc., CONMED Corporation, C. R. Bard, Inc., Braun Melsungen AG, Smith & Nephew, DePuy Synthes, Stryker Corporation, Zimmer Biomet Holdings, Inc., and Arthrex Inc.
Global Companion Diagnostic Tests in Oncology Market: Snapshot
The global companion diagnostic tests in oncology market is expected to register phenomenal pace owing to increasing adoption of new tests, and rising shift from blockbuster drugs to personalized medicines, and targeted therapies. Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer. Increasing focus on research and development by various pharmaceutical and biotechnology companies, along with medical device companies, and increasing funding and grants for cancer research by various government agencies have led to high adoption of companion diagnostic tests in oncology. According to the research report, the global companion diagnostic tests in oncology market is expected to be worth US$13.6 bn by the end of 2025 from US$3.5 bn in 2016. During the forecast period of 2017 and 2025, the global market is projected to rise at a CAGR of 16.8%.
This 232 page report gives readers a comprehensive overview of the companion diagnostic tests in oncology market. Browse through 42 data tables and 89 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/companion-diagnostic-tests-market.html
EGFR Biomarker to Remain Popular Amongst Pharmaceutical Companies
Among the biomarker segment, the EGFR biomarker segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. It is expected to register highest CAGR during the forecast period of 2017-2025, owing to major factors such as increasing incidence of lung cancer, and rising R&D in biomarker segment. The HER2 and KRAS biomarkers are expected to register high CAGR during the forecast period, due to increasing incidence of cancer, and rising adoption of biomarker by pharmaceutical companies and research institutes. Analysts expect that the EGFR biomarker segment will register a CAGR of 18.4% over the forecast period.
Among the cancer types segment, the breast cancer segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. However lung cancer segment is expected to register highest CAGR during the forecast period of 2017-2025, owing to increasing incidence of lung cancer in developing countries. This shift is attributable to the increased smoking and rising biomarker research for the lung cancer treatment. According to statistics from the World Health Organization (WHO), in 2013, an estimated 1.9 million new cases of lung cancer were diagnosed, and the stats reveled that less developed regions including the emerging countries such as China, India, and other countries, had the highest incidence of lung cancer, owing to rising smoking habits and poor air quality in these countries.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving companion diagnostic tests in oncology market during 2017 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4684
North America to Remain Dominant with Higher Acceptance of Technologies
Geographically, the global companion diagnostic tests in oncology market is segmented into North America, the Middle East and Africa, Asia Pacific, Europe, and Latin America. Analysts expect that North America will continue to dominate the global market due to the higher acceptance of technology in the region. Furthermore, better rate of diagnoses in the region is also likely to favor the regional market’s growth. By the end of 2025, the regional market is projected to account for a share of 37.5% in the global market. On the other hand, Asia Pacific is also expected to offer lucrative opportunities due to high rate of unmet medical needs in the emerging economies of the region.
Major players having presence in the global companion diagnostic tests in oncology market include F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others.
Global Cancer Biomarkers Market: Snapshot
Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer biomarkers market. The global market for cancer biomarkers is expected to grow at an exponential rate benefiting from the recent advances in technology, favorable government initiatives and funding.
Moreover, the development in companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer biomarkers. Cancer biomarker is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved.
This 157 page report gives readers a comprehensive overview of the cancer biomarkers market. Browse through 18 data tables and 64 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/cancer-biomarkers-market.html
Besides this, the cancer biomarkers market is expected to gain from the rising geriatric population, increasing incidences of cancer, and increasing prevalence of tumor. Technological advancements in the field of biomarkers resulting in new and innovative products have increased the safety, improved efficacy and reduced the side effects. Spurred by these factors, the global cancer biomarkers market is forecast to exhibit a CAGR of 11.8% between 2017 and 2025. At this pace, the market is expected to reach US$27.63 bn by the end of 2025 from US$10.25 bn in 2016.
Lung Cancer Emerges as Leading Segment Based on Disease Indication
The CTC tests segment by test type accounted the largest share of the global cancer biomarkers market in 2016, and is expected to dominate the market during the forecast period from 2017 to 2025. Factors such as increase in prevalence of the various types of tumor and increasing incidences of cancer related to the vital organs drives the CTC tests segment. Although associated with non-drivers of selection, such as quick and easy order processing and availability from a contracted manufacturer, the cancer biomarkers market presents immense competition for new market players.
The lung cancer segment in terms of disease indication has the largest market share of the global cancer biomarkers market in 2016, and is expected to grow during the forecast period due to increasing prevalence of lung cancer in developing countries, growing cigarette smoking among the population, rising geriatric population, and technological advancements with regard to lesser side effects associated with biomarkers test and early detection of the illness drive demand for lung cancer diagnosis globally.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving cancer biomarkers market during 2017 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=479
North America to Remain Dominant Regional Market through Forecast Period
North America dominated the global cancer biomarkers market in 2016 and is expected to remain dominant through the forecast period. This is due to high prevalence of cancer, increasing health care expenditure leading to increase in demand for better diagnostic tests and health care services, and number of technological advancements in the field of cancer biomarkers. However, the market in Asia Pacific is projected to register a significant growth rate by 2025 due to availability of large patient pool and increasing awareness about health. In addition, high percentage of geriatric population, and increasing disposable income are expected to propel the market.
Major players operating in the global cancer biomarkers market include Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc., are among others.